nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ALB—Captopril—systemic scleroderma	0.0642	0.11	CbGbCtD
Fluoxetine—CYP1A2—Pentoxifylline—systemic scleroderma	0.0513	0.0879	CbGbCtD
Fluoxetine—ALB—Mycophenolate mofetil—systemic scleroderma	0.0505	0.0866	CbGbCtD
Fluoxetine—CYP1A2—Leflunomide—systemic scleroderma	0.0489	0.0839	CbGbCtD
Fluoxetine—ABCB1—Lisinopril—systemic scleroderma	0.0448	0.0769	CbGbCtD
Fluoxetine—CYP2C9—Leflunomide—systemic scleroderma	0.0441	0.0756	CbGbCtD
Fluoxetine—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.0406	0.0696	CbGbCtD
Fluoxetine—ALB—Prednisone—systemic scleroderma	0.0404	0.0693	CbGbCtD
Fluoxetine—ABCB1—Captopril—systemic scleroderma	0.0336	0.0576	CbGbCtD
Fluoxetine—CYP2D6—Captopril—systemic scleroderma	0.0316	0.0542	CbGbCtD
Fluoxetine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0264	0.0453	CbGbCtD
Fluoxetine—CYP2C19—Prednisone—systemic scleroderma	0.0262	0.0449	CbGbCtD
Fluoxetine—ABCB1—Prednisone—systemic scleroderma	0.0211	0.0362	CbGbCtD
Fluoxetine—ALB—Methotrexate—systemic scleroderma	0.0203	0.0348	CbGbCtD
Fluoxetine—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0158	0.0272	CbGbCtD
Fluoxetine—CYP3A4—Prednisone—systemic scleroderma	0.0127	0.0217	CbGbCtD
Fluoxetine—CYP2C9—cardial valve—systemic scleroderma	0.0111	0.3	CbGeAlD
Fluoxetine—ABCB1—Methotrexate—systemic scleroderma	0.0106	0.0182	CbGbCtD
Fluoxetine—HTR2A—myenteric nerve plexus—systemic scleroderma	0.00522	0.141	CbGeAlD
Fluoxetine—HTR2A—pulmonary artery—systemic scleroderma	0.00369	0.1	CbGeAlD
Fluoxetine—HTR2A—artery—systemic scleroderma	0.00137	0.0371	CbGeAlD
Fluoxetine—HTR2A—endothelium—systemic scleroderma	0.00116	0.0313	CbGeAlD
Fluoxetine—HTR2A—blood vessel—systemic scleroderma	0.00107	0.0289	CbGeAlD
Fluoxetine—SIGMAR1—smooth muscle tissue—systemic scleroderma	0.000939	0.0254	CbGeAlD
Fluoxetine—SLC6A4—digestive system—systemic scleroderma	0.000747	0.0202	CbGeAlD
Fluoxetine—ORM1—lung—systemic scleroderma	0.000732	0.0198	CbGeAlD
Fluoxetine—SIGMAR1—tendon—systemic scleroderma	0.000706	0.0191	CbGeAlD
Fluoxetine—ABCB1—blood vessel—systemic scleroderma	0.000699	0.0189	CbGeAlD
Fluoxetine—SLC6A4—lung—systemic scleroderma	0.000623	0.0169	CbGeAlD
Fluoxetine—SIGMAR1—lung—systemic scleroderma	0.000619	0.0168	CbGeAlD
Fluoxetine—CYP2C19—digestive system—systemic scleroderma	0.000619	0.0167	CbGeAlD
Fluoxetine—CYP2B6—skin of body—systemic scleroderma	0.000605	0.0164	CbGeAlD
Fluoxetine—SLC6A2—lung—systemic scleroderma	0.000549	0.0149	CbGeAlD
Fluoxetine—HTR2A—connective tissue—systemic scleroderma	0.000547	0.0148	CbGeAlD
Fluoxetine—CYP1A2—digestive system—systemic scleroderma	0.000505	0.0137	CbGeAlD
Fluoxetine—HTR2A—smooth muscle tissue—systemic scleroderma	0.0005	0.0135	CbGeAlD
Fluoxetine—CYP3A5—digestive system—systemic scleroderma	0.000487	0.0132	CbGeAlD
Fluoxetine—CYP2B6—digestive system—systemic scleroderma	0.000484	0.0131	CbGeAlD
Fluoxetine—CYP2C9—digestive system—systemic scleroderma	0.00048	0.013	CbGeAlD
Fluoxetine—CYP1A2—lung—systemic scleroderma	0.000422	0.0114	CbGeAlD
Fluoxetine—CYP3A5—lung—systemic scleroderma	0.000407	0.011	CbGeAlD
Fluoxetine—CYP2B6—lung—systemic scleroderma	0.000404	0.0109	CbGeAlD
Fluoxetine—HTR2A—digestive system—systemic scleroderma	0.000395	0.0107	CbGeAlD
Fluoxetine—HTR2A—tendon—systemic scleroderma	0.000376	0.0102	CbGeAlD
Fluoxetine—CYP3A4—digestive system—systemic scleroderma	0.000366	0.0099	CbGeAlD
Fluoxetine—CYP2D6—digestive system—systemic scleroderma	0.00036	0.00974	CbGeAlD
Fluoxetine—HTR2A—lung—systemic scleroderma	0.00033	0.00893	CbGeAlD
Fluoxetine—ABCB1—digestive system—systemic scleroderma	0.000259	0.007	CbGeAlD
Fluoxetine—ABCB1—lung—systemic scleroderma	0.000216	0.00585	CbGeAlD
Fluoxetine—Weight decreased—Prednisone—systemic scleroderma	0.00011	0.000289	CcSEcCtD
Fluoxetine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00011	0.000288	CcSEcCtD
Fluoxetine—Hyperglycaemia—Prednisone—systemic scleroderma	0.000109	0.000288	CcSEcCtD
Fluoxetine—Cough—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000286	CcSEcCtD
Fluoxetine—Hypotension—Lisinopril—systemic scleroderma	0.000108	0.000285	CcSEcCtD
Fluoxetine—Dizziness—Captopril—systemic scleroderma	0.000108	0.000285	CcSEcCtD
Fluoxetine—Liver function test abnormal—Methotrexate—systemic scleroderma	0.000108	0.000285	CcSEcCtD
Fluoxetine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000284	CcSEcCtD
Fluoxetine—Depression—Prednisone—systemic scleroderma	0.000108	0.000284	CcSEcCtD
Fluoxetine—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000108	0.000283	CcSEcCtD
Fluoxetine—Urticaria—Leflunomide—systemic scleroderma	0.000107	0.000282	CcSEcCtD
Fluoxetine—Abdominal pain—Leflunomide—systemic scleroderma	0.000107	0.000281	CcSEcCtD
Fluoxetine—Body temperature increased—Leflunomide—systemic scleroderma	0.000107	0.000281	CcSEcCtD
Fluoxetine—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000107	0.00028	CcSEcCtD
Fluoxetine—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000106	0.000279	CcSEcCtD
Fluoxetine—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000279	CcSEcCtD
Fluoxetine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000279	CcSEcCtD
Fluoxetine—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000279	CcSEcCtD
Fluoxetine—Neuropathy peripheral—Prednisone—systemic scleroderma	0.000106	0.000279	CcSEcCtD
Fluoxetine—Myocardial infarction—Prednisone—systemic scleroderma	0.000106	0.000279	CcSEcCtD
Fluoxetine—Breast disorder—Methotrexate—systemic scleroderma	0.000106	0.000279	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000106	0.000278	CcSEcCtD
Fluoxetine—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000106	0.000278	CcSEcCtD
Fluoxetine—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	0.000106	0.000278	CcSEcCtD
Fluoxetine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000105	0.000277	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000105	0.000277	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000277	CcSEcCtD
Fluoxetine—Insomnia—Lisinopril—systemic scleroderma	0.000105	0.000276	CcSEcCtD
Fluoxetine—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000105	0.000276	CcSEcCtD
Fluoxetine—Paraesthesia—Lisinopril—systemic scleroderma	0.000104	0.000274	CcSEcCtD
Fluoxetine—Vomiting—Captopril—systemic scleroderma	0.000104	0.000274	CcSEcCtD
Fluoxetine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000104	0.000273	CcSEcCtD
Fluoxetine—Dyspnoea—Lisinopril—systemic scleroderma	0.000103	0.000272	CcSEcCtD
Fluoxetine—Rash—Captopril—systemic scleroderma	0.000103	0.000272	CcSEcCtD
Fluoxetine—Dermatitis—Captopril—systemic scleroderma	0.000103	0.000272	CcSEcCtD
Fluoxetine—Somnolence—Lisinopril—systemic scleroderma	0.000103	0.000272	CcSEcCtD
Fluoxetine—Headache—Captopril—systemic scleroderma	0.000103	0.00027	CcSEcCtD
Fluoxetine—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000103	0.00027	CcSEcCtD
Fluoxetine—Dyspepsia—Lisinopril—systemic scleroderma	0.000102	0.000269	CcSEcCtD
Fluoxetine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000102	0.000268	CcSEcCtD
Fluoxetine—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000102	0.000268	CcSEcCtD
Fluoxetine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000102	0.000268	CcSEcCtD
Fluoxetine—Asthma—Methotrexate—systemic scleroderma	0.000101	0.000267	CcSEcCtD
Fluoxetine—Infection—Mycophenolate mofetil—systemic scleroderma	0.000101	0.000266	CcSEcCtD
Fluoxetine—Decreased appetite—Lisinopril—systemic scleroderma	0.000101	0.000266	CcSEcCtD
Fluoxetine—Eosinophilia—Methotrexate—systemic scleroderma	0.0001	0.000264	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.0001	0.000264	CcSEcCtD
Fluoxetine—Fatigue—Lisinopril—systemic scleroderma	0.0001	0.000263	CcSEcCtD
Fluoxetine—Shock—Mycophenolate mofetil—systemic scleroderma	0.0001	0.000263	CcSEcCtD
Fluoxetine—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	9.96e-05	0.000262	CcSEcCtD
Fluoxetine—Hypersensitivity—Leflunomide—systemic scleroderma	9.95e-05	0.000262	CcSEcCtD
Fluoxetine—Pancreatitis—Methotrexate—systemic scleroderma	9.93e-05	0.000261	CcSEcCtD
Fluoxetine—Pain—Lisinopril—systemic scleroderma	9.93e-05	0.000261	CcSEcCtD
Fluoxetine—Constipation—Lisinopril—systemic scleroderma	9.93e-05	0.000261	CcSEcCtD
Fluoxetine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	9.93e-05	0.000261	CcSEcCtD
Fluoxetine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	9.88e-05	0.00026	CcSEcCtD
Fluoxetine—Bradycardia—Prednisone—systemic scleroderma	9.88e-05	0.00026	CcSEcCtD
Fluoxetine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	9.83e-05	0.000259	CcSEcCtD
Fluoxetine—Diarrhoea—Azathioprine—systemic scleroderma	9.79e-05	0.000258	CcSEcCtD
Fluoxetine—Haemoglobin—Prednisone—systemic scleroderma	9.75e-05	0.000257	CcSEcCtD
Fluoxetine—Nausea—Captopril—systemic scleroderma	9.74e-05	0.000256	CcSEcCtD
Fluoxetine—Haemorrhage—Prednisone—systemic scleroderma	9.7e-05	0.000255	CcSEcCtD
Fluoxetine—Anorexia—Mycophenolate mofetil—systemic scleroderma	9.69e-05	0.000255	CcSEcCtD
Fluoxetine—Asthenia—Leflunomide—systemic scleroderma	9.69e-05	0.000255	CcSEcCtD
Fluoxetine—Hallucination—Prednisone—systemic scleroderma	9.66e-05	0.000254	CcSEcCtD
Fluoxetine—Pancytopenia—Methotrexate—systemic scleroderma	9.62e-05	0.000253	CcSEcCtD
Fluoxetine—Feeling abnormal—Lisinopril—systemic scleroderma	9.57e-05	0.000252	CcSEcCtD
Fluoxetine—Pruritus—Leflunomide—systemic scleroderma	9.56e-05	0.000251	CcSEcCtD
Fluoxetine—Hypotension—Mycophenolate mofetil—systemic scleroderma	9.5e-05	0.00025	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Lisinopril—systemic scleroderma	9.49e-05	0.00025	CcSEcCtD
Fluoxetine—Dysuria—Methotrexate—systemic scleroderma	9.47e-05	0.000249	CcSEcCtD
Fluoxetine—Dizziness—Azathioprine—systemic scleroderma	9.46e-05	0.000249	CcSEcCtD
Fluoxetine—Upper respiratory tract infection—Methotrexate—systemic scleroderma	9.42e-05	0.000248	CcSEcCtD
Fluoxetine—Erectile dysfunction—Methotrexate—systemic scleroderma	9.33e-05	0.000246	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	9.27e-05	0.000244	CcSEcCtD
Fluoxetine—Photosensitivity reaction—Methotrexate—systemic scleroderma	9.25e-05	0.000243	CcSEcCtD
Fluoxetine—Asthenia—Mycophenolic acid—systemic scleroderma	9.25e-05	0.000243	CcSEcCtD
Fluoxetine—Diarrhoea—Leflunomide—systemic scleroderma	9.24e-05	0.000243	CcSEcCtD
Fluoxetine—Urticaria—Lisinopril—systemic scleroderma	9.22e-05	0.000243	CcSEcCtD
Fluoxetine—Insomnia—Mycophenolate mofetil—systemic scleroderma	9.2e-05	0.000242	CcSEcCtD
Fluoxetine—Body temperature increased—Lisinopril—systemic scleroderma	9.18e-05	0.000241	CcSEcCtD
Fluoxetine—Abdominal pain—Lisinopril—systemic scleroderma	9.18e-05	0.000241	CcSEcCtD
Fluoxetine—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	9.13e-05	0.00024	CcSEcCtD
Fluoxetine—Pruritus—Mycophenolic acid—systemic scleroderma	9.12e-05	0.00024	CcSEcCtD
Fluoxetine—Vomiting—Azathioprine—systemic scleroderma	9.1e-05	0.000239	CcSEcCtD
Fluoxetine—Pneumonia—Methotrexate—systemic scleroderma	9.09e-05	0.000239	CcSEcCtD
Fluoxetine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	9.07e-05	0.000239	CcSEcCtD
Fluoxetine—Somnolence—Mycophenolate mofetil—systemic scleroderma	9.04e-05	0.000238	CcSEcCtD
Fluoxetine—Drowsiness—Methotrexate—systemic scleroderma	9.03e-05	0.000238	CcSEcCtD
Fluoxetine—Rash—Azathioprine—systemic scleroderma	9.02e-05	0.000237	CcSEcCtD
Fluoxetine—Dermatitis—Azathioprine—systemic scleroderma	9.01e-05	0.000237	CcSEcCtD
Fluoxetine—Depression—Methotrexate—systemic scleroderma	9.01e-05	0.000237	CcSEcCtD
Fluoxetine—Headache—Azathioprine—systemic scleroderma	8.96e-05	0.000236	CcSEcCtD
Fluoxetine—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	8.96e-05	0.000236	CcSEcCtD
Fluoxetine—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	8.95e-05	0.000236	CcSEcCtD
Fluoxetine—Dizziness—Leflunomide—systemic scleroderma	8.93e-05	0.000235	CcSEcCtD
Fluoxetine—Renal failure—Methotrexate—systemic scleroderma	8.88e-05	0.000234	CcSEcCtD
Fluoxetine—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	8.84e-05	0.000233	CcSEcCtD
Fluoxetine—Diarrhoea—Mycophenolic acid—systemic scleroderma	8.82e-05	0.000232	CcSEcCtD
Fluoxetine—Stomatitis—Methotrexate—systemic scleroderma	8.81e-05	0.000232	CcSEcCtD
Fluoxetine—Conjunctivitis—Methotrexate—systemic scleroderma	8.78e-05	0.000231	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	8.78e-05	0.000231	CcSEcCtD
Fluoxetine—Pain—Mycophenolate mofetil—systemic scleroderma	8.7e-05	0.000229	CcSEcCtD
Fluoxetine—Constipation—Mycophenolate mofetil—systemic scleroderma	8.7e-05	0.000229	CcSEcCtD
Fluoxetine—Arrhythmia—Prednisone—systemic scleroderma	8.67e-05	0.000228	CcSEcCtD
Fluoxetine—Sweating—Methotrexate—systemic scleroderma	8.66e-05	0.000228	CcSEcCtD
Fluoxetine—Haematuria—Methotrexate—systemic scleroderma	8.61e-05	0.000227	CcSEcCtD
Fluoxetine—Vomiting—Leflunomide—systemic scleroderma	8.59e-05	0.000226	CcSEcCtD
Fluoxetine—Alopecia—Prednisone—systemic scleroderma	8.57e-05	0.000226	CcSEcCtD
Fluoxetine—Hypersensitivity—Lisinopril—systemic scleroderma	8.55e-05	0.000225	CcSEcCtD
Fluoxetine—Dizziness—Mycophenolic acid—systemic scleroderma	8.52e-05	0.000224	CcSEcCtD
Fluoxetine—Epistaxis—Methotrexate—systemic scleroderma	8.52e-05	0.000224	CcSEcCtD
Fluoxetine—Rash—Leflunomide—systemic scleroderma	8.52e-05	0.000224	CcSEcCtD
Fluoxetine—Dermatitis—Leflunomide—systemic scleroderma	8.51e-05	0.000224	CcSEcCtD
Fluoxetine—Mental disorder—Prednisone—systemic scleroderma	8.5e-05	0.000224	CcSEcCtD
Fluoxetine—Nausea—Azathioprine—systemic scleroderma	8.5e-05	0.000224	CcSEcCtD
Fluoxetine—Headache—Leflunomide—systemic scleroderma	8.46e-05	0.000223	CcSEcCtD
Fluoxetine—Malnutrition—Prednisone—systemic scleroderma	8.45e-05	0.000222	CcSEcCtD
Fluoxetine—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	8.38e-05	0.000221	CcSEcCtD
Fluoxetine—Asthenia—Lisinopril—systemic scleroderma	8.33e-05	0.000219	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	8.32e-05	0.000219	CcSEcCtD
Fluoxetine—Pruritus—Lisinopril—systemic scleroderma	8.21e-05	0.000216	CcSEcCtD
Fluoxetine—Vomiting—Mycophenolic acid—systemic scleroderma	8.19e-05	0.000216	CcSEcCtD
Fluoxetine—Haemoglobin—Methotrexate—systemic scleroderma	8.15e-05	0.000214	CcSEcCtD
Fluoxetine—Rash—Mycophenolic acid—systemic scleroderma	8.13e-05	0.000214	CcSEcCtD
Fluoxetine—Dermatitis—Mycophenolic acid—systemic scleroderma	8.12e-05	0.000214	CcSEcCtD
Fluoxetine—Hepatitis—Methotrexate—systemic scleroderma	8.11e-05	0.000213	CcSEcCtD
Fluoxetine—Haemorrhage—Methotrexate—systemic scleroderma	8.11e-05	0.000213	CcSEcCtD
Fluoxetine—Urticaria—Mycophenolate mofetil—systemic scleroderma	8.08e-05	0.000213	CcSEcCtD
Fluoxetine—Headache—Mycophenolic acid—systemic scleroderma	8.07e-05	0.000212	CcSEcCtD
Fluoxetine—Pharyngitis—Methotrexate—systemic scleroderma	8.05e-05	0.000212	CcSEcCtD
Fluoxetine—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	8.04e-05	0.000212	CcSEcCtD
Fluoxetine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	8.04e-05	0.000212	CcSEcCtD
Fluoxetine—Nausea—Leflunomide—systemic scleroderma	8.02e-05	0.000211	CcSEcCtD
Fluoxetine—Diarrhoea—Lisinopril—systemic scleroderma	7.94e-05	0.000209	CcSEcCtD
Fluoxetine—Ill-defined disorder—Prednisone—systemic scleroderma	7.84e-05	0.000206	CcSEcCtD
Fluoxetine—Visual impairment—Methotrexate—systemic scleroderma	7.82e-05	0.000206	CcSEcCtD
Fluoxetine—Anaemia—Prednisone—systemic scleroderma	7.81e-05	0.000205	CcSEcCtD
Fluoxetine—Agitation—Prednisone—systemic scleroderma	7.76e-05	0.000204	CcSEcCtD
Fluoxetine—Angioedema—Prednisone—systemic scleroderma	7.72e-05	0.000203	CcSEcCtD
Fluoxetine—Dizziness—Lisinopril—systemic scleroderma	7.68e-05	0.000202	CcSEcCtD
Fluoxetine—Erythema multiforme—Methotrexate—systemic scleroderma	7.67e-05	0.000202	CcSEcCtD
Fluoxetine—Nausea—Mycophenolic acid—systemic scleroderma	7.66e-05	0.000201	CcSEcCtD
Fluoxetine—Malaise—Prednisone—systemic scleroderma	7.62e-05	0.0002	CcSEcCtD
Fluoxetine—Vertigo—Prednisone—systemic scleroderma	7.59e-05	0.0002	CcSEcCtD
Fluoxetine—Syncope—Prednisone—systemic scleroderma	7.58e-05	0.000199	CcSEcCtD
Fluoxetine—Tinnitus—Methotrexate—systemic scleroderma	7.56e-05	0.000199	CcSEcCtD
Fluoxetine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	7.49e-05	0.000197	CcSEcCtD
Fluoxetine—Loss of consciousness—Prednisone—systemic scleroderma	7.42e-05	0.000195	CcSEcCtD
Fluoxetine—Vomiting—Lisinopril—systemic scleroderma	7.38e-05	0.000194	CcSEcCtD
Fluoxetine—Rash—Lisinopril—systemic scleroderma	7.32e-05	0.000193	CcSEcCtD
Fluoxetine—Convulsion—Prednisone—systemic scleroderma	7.32e-05	0.000193	CcSEcCtD
Fluoxetine—Dermatitis—Lisinopril—systemic scleroderma	7.31e-05	0.000192	CcSEcCtD
Fluoxetine—Asthenia—Mycophenolate mofetil—systemic scleroderma	7.3e-05	0.000192	CcSEcCtD
Fluoxetine—Hypertension—Prednisone—systemic scleroderma	7.29e-05	0.000192	CcSEcCtD
Fluoxetine—Chills—Methotrexate—systemic scleroderma	7.28e-05	0.000191	CcSEcCtD
Fluoxetine—Headache—Lisinopril—systemic scleroderma	7.27e-05	0.000191	CcSEcCtD
Fluoxetine—Pruritus—Mycophenolate mofetil—systemic scleroderma	7.2e-05	0.000189	CcSEcCtD
Fluoxetine—Arthralgia—Prednisone—systemic scleroderma	7.19e-05	0.000189	CcSEcCtD
Fluoxetine—Myalgia—Prednisone—systemic scleroderma	7.19e-05	0.000189	CcSEcCtD
Fluoxetine—Anxiety—Prednisone—systemic scleroderma	7.17e-05	0.000189	CcSEcCtD
Fluoxetine—Alopecia—Methotrexate—systemic scleroderma	7.17e-05	0.000189	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	7.14e-05	0.000188	CcSEcCtD
Fluoxetine—Discomfort—Prednisone—systemic scleroderma	7.11e-05	0.000187	CcSEcCtD
Fluoxetine—Mental disorder—Methotrexate—systemic scleroderma	7.1e-05	0.000187	CcSEcCtD
Fluoxetine—Malnutrition—Methotrexate—systemic scleroderma	7.06e-05	0.000186	CcSEcCtD
Fluoxetine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.96e-05	0.000183	CcSEcCtD
Fluoxetine—Dysgeusia—Methotrexate—systemic scleroderma	6.91e-05	0.000182	CcSEcCtD
Fluoxetine—Nausea—Lisinopril—systemic scleroderma	6.9e-05	0.000181	CcSEcCtD
Fluoxetine—Anaphylactic shock—Prednisone—systemic scleroderma	6.89e-05	0.000181	CcSEcCtD
Fluoxetine—Infection—Prednisone—systemic scleroderma	6.85e-05	0.00018	CcSEcCtD
Fluoxetine—Back pain—Methotrexate—systemic scleroderma	6.83e-05	0.00018	CcSEcCtD
Fluoxetine—Shock—Prednisone—systemic scleroderma	6.78e-05	0.000178	CcSEcCtD
Fluoxetine—Tachycardia—Prednisone—systemic scleroderma	6.73e-05	0.000177	CcSEcCtD
Fluoxetine—Dizziness—Mycophenolate mofetil—systemic scleroderma	6.73e-05	0.000177	CcSEcCtD
Fluoxetine—Skin disorder—Prednisone—systemic scleroderma	6.7e-05	0.000176	CcSEcCtD
Fluoxetine—Hyperhidrosis—Prednisone—systemic scleroderma	6.66e-05	0.000175	CcSEcCtD
Fluoxetine—Anorexia—Prednisone—systemic scleroderma	6.57e-05	0.000173	CcSEcCtD
Fluoxetine—Ill-defined disorder—Methotrexate—systemic scleroderma	6.55e-05	0.000172	CcSEcCtD
Fluoxetine—Anaemia—Methotrexate—systemic scleroderma	6.53e-05	0.000172	CcSEcCtD
Fluoxetine—Vomiting—Mycophenolate mofetil—systemic scleroderma	6.47e-05	0.00017	CcSEcCtD
Fluoxetine—Rash—Mycophenolate mofetil—systemic scleroderma	6.41e-05	0.000169	CcSEcCtD
Fluoxetine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	6.41e-05	0.000169	CcSEcCtD
Fluoxetine—Headache—Mycophenolate mofetil—systemic scleroderma	6.37e-05	0.000168	CcSEcCtD
Fluoxetine—Malaise—Methotrexate—systemic scleroderma	6.37e-05	0.000168	CcSEcCtD
Fluoxetine—Vertigo—Methotrexate—systemic scleroderma	6.34e-05	0.000167	CcSEcCtD
Fluoxetine—Leukopenia—Methotrexate—systemic scleroderma	6.32e-05	0.000166	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	6.28e-05	0.000165	CcSEcCtD
Fluoxetine—Insomnia—Prednisone—systemic scleroderma	6.24e-05	0.000164	CcSEcCtD
Fluoxetine—Paraesthesia—Prednisone—systemic scleroderma	6.19e-05	0.000163	CcSEcCtD
Fluoxetine—Cough—Methotrexate—systemic scleroderma	6.16e-05	0.000162	CcSEcCtD
Fluoxetine—Convulsion—Methotrexate—systemic scleroderma	6.12e-05	0.000161	CcSEcCtD
Fluoxetine—Dyspepsia—Prednisone—systemic scleroderma	6.07e-05	0.00016	CcSEcCtD
Fluoxetine—Nausea—Mycophenolate mofetil—systemic scleroderma	6.04e-05	0.000159	CcSEcCtD
Fluoxetine—Myalgia—Methotrexate—systemic scleroderma	6.01e-05	0.000158	CcSEcCtD
Fluoxetine—Chest pain—Methotrexate—systemic scleroderma	6.01e-05	0.000158	CcSEcCtD
Fluoxetine—Arthralgia—Methotrexate—systemic scleroderma	6.01e-05	0.000158	CcSEcCtD
Fluoxetine—Decreased appetite—Prednisone—systemic scleroderma	5.99e-05	0.000158	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	5.97e-05	0.000157	CcSEcCtD
Fluoxetine—Fatigue—Prednisone—systemic scleroderma	5.94e-05	0.000156	CcSEcCtD
Fluoxetine—Discomfort—Methotrexate—systemic scleroderma	5.94e-05	0.000156	CcSEcCtD
Fluoxetine—Constipation—Prednisone—systemic scleroderma	5.9e-05	0.000155	CcSEcCtD
Fluoxetine—Confusional state—Methotrexate—systemic scleroderma	5.81e-05	0.000153	CcSEcCtD
Fluoxetine—Anaphylactic shock—Methotrexate—systemic scleroderma	5.76e-05	0.000152	CcSEcCtD
Fluoxetine—Infection—Methotrexate—systemic scleroderma	5.72e-05	0.000151	CcSEcCtD
Fluoxetine—Feeling abnormal—Prednisone—systemic scleroderma	5.68e-05	0.000149	CcSEcCtD
Fluoxetine—Thrombocytopenia—Methotrexate—systemic scleroderma	5.64e-05	0.000148	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Prednisone—systemic scleroderma	5.64e-05	0.000148	CcSEcCtD
Fluoxetine—Skin disorder—Methotrexate—systemic scleroderma	5.6e-05	0.000147	CcSEcCtD
Fluoxetine—Hyperhidrosis—Methotrexate—systemic scleroderma	5.57e-05	0.000147	CcSEcCtD
Fluoxetine—Anorexia—Methotrexate—systemic scleroderma	5.49e-05	0.000145	CcSEcCtD
Fluoxetine—Urticaria—Prednisone—systemic scleroderma	5.48e-05	0.000144	CcSEcCtD
Fluoxetine—Abdominal pain—Prednisone—systemic scleroderma	5.45e-05	0.000143	CcSEcCtD
Fluoxetine—Body temperature increased—Prednisone—systemic scleroderma	5.45e-05	0.000143	CcSEcCtD
Fluoxetine—Hypotension—Methotrexate—systemic scleroderma	5.38e-05	0.000142	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	5.25e-05	0.000138	CcSEcCtD
Fluoxetine—Insomnia—Methotrexate—systemic scleroderma	5.21e-05	0.000137	CcSEcCtD
Fluoxetine—Paraesthesia—Methotrexate—systemic scleroderma	5.17e-05	0.000136	CcSEcCtD
Fluoxetine—Dyspnoea—Methotrexate—systemic scleroderma	5.14e-05	0.000135	CcSEcCtD
Fluoxetine—Somnolence—Methotrexate—systemic scleroderma	5.12e-05	0.000135	CcSEcCtD
Fluoxetine—Hypersensitivity—Prednisone—systemic scleroderma	5.08e-05	0.000134	CcSEcCtD
Fluoxetine—Dyspepsia—Methotrexate—systemic scleroderma	5.07e-05	0.000133	CcSEcCtD
Fluoxetine—Decreased appetite—Methotrexate—systemic scleroderma	5.01e-05	0.000132	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.97e-05	0.000131	CcSEcCtD
Fluoxetine—Fatigue—Methotrexate—systemic scleroderma	4.97e-05	0.000131	CcSEcCtD
Fluoxetine—Asthenia—Prednisone—systemic scleroderma	4.95e-05	0.00013	CcSEcCtD
Fluoxetine—Pain—Methotrexate—systemic scleroderma	4.93e-05	0.00013	CcSEcCtD
Fluoxetine—Pruritus—Prednisone—systemic scleroderma	4.88e-05	0.000128	CcSEcCtD
Fluoxetine—Feeling abnormal—Methotrexate—systemic scleroderma	4.75e-05	0.000125	CcSEcCtD
Fluoxetine—Diarrhoea—Prednisone—systemic scleroderma	4.72e-05	0.000124	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.71e-05	0.000124	CcSEcCtD
Fluoxetine—Urticaria—Methotrexate—systemic scleroderma	4.58e-05	0.00012	CcSEcCtD
Fluoxetine—Dizziness—Prednisone—systemic scleroderma	4.56e-05	0.00012	CcSEcCtD
Fluoxetine—Body temperature increased—Methotrexate—systemic scleroderma	4.55e-05	0.00012	CcSEcCtD
Fluoxetine—Abdominal pain—Methotrexate—systemic scleroderma	4.55e-05	0.00012	CcSEcCtD
Fluoxetine—Vomiting—Prednisone—systemic scleroderma	4.38e-05	0.000115	CcSEcCtD
Fluoxetine—Rash—Prednisone—systemic scleroderma	4.35e-05	0.000114	CcSEcCtD
Fluoxetine—Dermatitis—Prednisone—systemic scleroderma	4.34e-05	0.000114	CcSEcCtD
Fluoxetine—Headache—Prednisone—systemic scleroderma	4.32e-05	0.000114	CcSEcCtD
Fluoxetine—Hypersensitivity—Methotrexate—systemic scleroderma	4.24e-05	0.000112	CcSEcCtD
Fluoxetine—Asthenia—Methotrexate—systemic scleroderma	4.13e-05	0.000109	CcSEcCtD
Fluoxetine—Nausea—Prednisone—systemic scleroderma	4.1e-05	0.000108	CcSEcCtD
Fluoxetine—Pruritus—Methotrexate—systemic scleroderma	4.08e-05	0.000107	CcSEcCtD
Fluoxetine—Diarrhoea—Methotrexate—systemic scleroderma	3.94e-05	0.000104	CcSEcCtD
Fluoxetine—Dizziness—Methotrexate—systemic scleroderma	3.81e-05	0.0001	CcSEcCtD
Fluoxetine—Vomiting—Methotrexate—systemic scleroderma	3.66e-05	9.64e-05	CcSEcCtD
Fluoxetine—Rash—Methotrexate—systemic scleroderma	3.63e-05	9.56e-05	CcSEcCtD
Fluoxetine—Dermatitis—Methotrexate—systemic scleroderma	3.63e-05	9.55e-05	CcSEcCtD
Fluoxetine—Headache—Methotrexate—systemic scleroderma	3.61e-05	9.5e-05	CcSEcCtD
Fluoxetine—Nausea—Methotrexate—systemic scleroderma	3.42e-05	9e-05	CcSEcCtD
